EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	11	trotter.in. and (tyrosine ADJ kinase).ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/12 17:06

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 10:57:59 ON 12 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 Jul 2007  VOL 147 ISS 3
FILE LAST UPDATED: 11 Jul 2007  (20070711/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitstr retable 16

L6   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2007 ACS on STN
AN   2003:836790  HCAPLUS
DN   139:337988
TI   Preparation of 1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine
     derivatives as tyrosine kinase inhibitors
IN   Trotter, B. Wesley
PA   Merck & Co., Inc., USA
SO   PCT Int. Appl., 78 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO2003086315        A2     20031023    2003WO-US12457          20030408
     WO2003086315        A3     20040108
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA---2480758        A1     20031023    2003CA-2480758          20030408
     AU2003223689        A1     20031027    2003AU-0223689          20030408
     EP---1496907        A2     20050119    2003EP-0719886          20030408
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP2005528387        T      20050922    2003JP-0583340          20030408
     US2005227988        A1     20051013    2004US-0510610          20041008
PRAI 2002US-372232P      P      20020412
     2003WO-US12457      W      20030408
OS   MARPAT 139:337988
GI
```



Q= $-(CR^{1?}{}_2)_n-X-(CR^{1?}{}_2)_p-V-(R^2)_q$

AB The present invention relates to benzazocine compds. [I; wherein R1a = H, (un)substituted C1-6 alkyl, OR4; R1b = H, (un)substituted C1-6 alkyl; X = a bond, CO, O, NR4, S(O)mR4, CO2R4, CON(R4)2; R1 = H, halo, OR4, NO2, S(O)mR4, cyano, each (un)substituted C1-10 alkyl, aryl, C2-6 alkenyl, C3-10 cycloalkyl, C2-6 alkynyl, or heterocyclyl, COR4, CO2R4, CON(R4)2, S(O)mN(R4)2, N(R4)2; V = H, CF3, aryl, heterocyclyl, C3-10 cycloalkyl; R2 = H, (un)substituted C1-10 alkyl, (CR1b)tOR4, halo, cyano, NO2, CF3, (CR1b)tN(R4)2, CO2R4, COR4, SO2R4, (CR1b)tNR4(CR1b)tR5, (CR1b)tS(O)mNR4, CO2R4, NR4COR4, each (un)substituted aryl or heterocyclyl; R4 = H, each (un)substituted C1-10 alkyl, C3-10 cycloalkyl, aryl, or heterocyclyl, CF3; R5 = each (un)substituted aryl or heterocyclyl; m = 0, 1, or 2; n, p, q, t = 0 to 6] or pharmaceutically acceptable salts or stereoisomers thereof. These compds. are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type tyrosine kinases (RTK) selected from insulin receptor (IR) kinase, insulin-like growth factor I receptor (IGF-IR) kinase and IRR receptor tyrosine kinase and non-receptor type tyrosine kinases (no data). They are useful for treating protein kinase, in particular RTK-related disorders such as cancer, diabetes, an autoimmune disorder, a hyperproliferation disorder, aging, acromegaly, and Crohn's disease and also treating retinal vascularization.

IT **615557-39-6P 615557-40-9P 615557-41-0P**
615557-42-1P 615557-43-2P 615557-44-3P
615557-45-4P 615557-46-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615557-39-6 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-40-9 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 · HCl

RN 615557-41-0 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-42-1 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-43-2 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 615557-42-1
CMF C21 H23 Br N2 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 615557-44-3 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl- (9CI) (CA INDEX NAME)



RN 615557-45-4 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-46-5 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



=> b reg
FILE 'REGISTRY' ENTERED AT 10:58:33 ON 12 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2007 HIGHEST RN 942193-36-4
DICTIONARY FILE UPDATES: 11 JUL 2007 HIGHEST RN 942193-36-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l9
L7 STR



NODE ATTRIBUTES:
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS R AT 11
NSPEC IS R AT 12
NSPEC IS R AT 13
NSPEC IS R AT 14
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L9 20 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED 292295 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 10:59:16 ON 12 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 12 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 11 Jul 2007 (20070711/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr l11

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:836790 HCAPLUS
DN 139:337988
TI Preparation of 1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine derivatives as tyrosine kinase inhibitors
IN Trotter, B. Wesley
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003086315	A2	20031023	2003WO-US12457	20030408 <--
	WO2003086315	A3	20040108		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2480758	A1	20031023	2003CA-2480758	20030408 <--
	AU2003223689	A1	20031027	2003AU-0223689	20030408 <--
	EP---1496907	A2	20050119	2003EP-0719886	20030408 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP2005528387	T	20050922	2003JP-0583340	20030408 <--
	US2005227988	A1	20051013	2004US-0510610	20041008 <--
PRAI	2002US-372232P	P	20020412 <--		
	2003WO-US12457	W	20030408 <--		

OS MARPAT 139:337988
GI



I

Q= $-(CR^{1?}{}_2)_n-X-(CR^{1?}{}_2)_p-V-(R^2)_q$

AB The present invention relates to benzazocine compds. [I; wherein R1a = H, (un)substituted C1-6 alkyl, OR4; R1b = H, (un)substituted C1-6 alkyl; X = a bond, CO, O, NR4, S(O)mR4, CO2R4, CON(R4)2; R1 = H, halo, OR4, NO2, S(O)mR4, cyano, each (un)substituted C1-10 alkyl, aryl, C2-6 alkenyl, C3-10 cycloalkyl, C2-6 alkynyl, or heterocyclyl, COR4, CO2R4, CON(R4)2, S(O)mN(R4)2, N(R4)2; V = H, CF3, aryl, heterocyclyl, C3-10 cycloalkyl; R2 = H, (un)substituted C1-10 alkyl, (CR1b)tOR4, halo, cyano, NO2, CF3, (CR1b)tN(R4)2, CO2R4, COR4, SO2R4, (CR1b)tNR4(CR1b)tR5, (CR1b)tS(O)mNR4, CO2R4, NR4COR4, each (un)substituted aryl or heterocyclyl; R4 = H, each (un)substituted C1-10 alkyl, C3-10 cycloalkyl, aryl, or heterocyclyl, CF3; R5 = each (un)substituted aryl or heterocyclyl; m = 0, 1, or 2; n, p, q, t = 0 to 6] or pharmaceutically acceptable salts or stereoisomers thereof. These compds. are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type tyrosine kinases (RTK) selected from insulin receptor (IR) kinase, insulin-like growth factor I receptor (IGF-IR) kinase and IRR receptor tyrosine kinase and non-receptor type tyrosine kinases (no data). They are useful for treating protein kinase,

in particular RTK-related disorders such as cancer, diabetes, an autoimmune disorder, a hyperproliferation disorder, aging, acromegaly, and Crohn's disease and also treating retinal vascularization.

IT **615557-39-6P 615557-40-9P 615557-41-0P**
615557-42-1P 615557-43-2P 615557-44-3P
615557-45-4P 615557-46-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

IT **615557-51-2P 615557-52-3P 615557-53-4P**
615557-54-5P 615557-55-6P 615557-56-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

IT **615557-39-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615557-39-6 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

=> d bib abs hitstr l12 tot

L12 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:543654 HCAPLUS
DN 137:338105
TI Stereoselective synthesis of bis(α-amino acid) derivatives isosteric of cysteine. Part 4
AU Ferioli, Federico; Piccinelli, Fabio; Porzi, Gianni; Sandri, Sergio
CS Dipartimento di Chimica 'G. Ciamician', Universita di Bologna, Bologna, 40126, Italy
SO Tetrahedron: Asymmetry (2002), 13(11), 1181-1187
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:338105
GI



I



II



III



IV

AB Enantiomerically pure α-alkyl derivs. of α,α'-diaminodicarboxylic acids isosteric of cysteine I, II and III (R1 = Me, CH2Ph, CH2OMe, CH2CH:CH2, CH2OH) have been synthesized starting from the glycine-derived chiral synthon IV via alkylation of bicyclic and tricyclic intermediates following by acid-hydrolysis.

IT **330160-19-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(stereoselective synthesis of 2,7-diaminocarboxylic acid derivs. from glycine-derived chiral synthon via alkylation and acid-hydrolysis)

RN 330160-19-5 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-3,11-bis[(1S)-1-phenylethyl]-, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **473920-00-2P 473920-01-3P 473920-03-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective synthesis of 2,7-diaminocarboxylic acid derivs. from glycine-derived chiral synthon via alkylation and acid-hydrolysis)

RN 473920-00-2 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-2-methyl-3,11-bis[(1S)-1-phenylethyl]-, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 473920-01-3 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-3,11-bis[(1S)-1-phenylethyl]-2-(phenylmethyl)-, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 473920-03-5 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-2-(methoxymethyl)-3,11-bis[(1S)-1-phenylethyl]-, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **473920-06-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective synthesis of 2,7-diaminocarboxylic acid derivs. from glycine-derived chiral synthon via alkylation and acid-hydrolysis)
RN 473920-06-8 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-3,11-bis[(1S)-1-phenylethyl]-2-(2-propenyl)-, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:32350 HCAPLUS
DN 134:237770
TI Stereoselective synthesis of α,α'-diamino-dicarboxylic acids. Part 2
AU Paradisi, F.; Porzi, G.; Rinaldi, S.; Sandri, S.
CS Dipartimento di Chimica 'G. Ciamician', Universita di Bologna, Bologna, 40126, Italy
SO Tetrahedron: Asymmetry (2000), 11(22), 4617-4622
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 134:237770

AB Enantiomerically pure α,α'-diamino dicarboxylic acids (R,R)- and (S,S)-2,7-diaminosuberic acid and (S,S)-o-phenylenebis(alanine) have been synthesized starting from the glycine-derived chiral synthon (S,S)-1,4-bis(1-phenylethyl)-2,5-piperazinedione.

IT **330160-19-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation of (R,R)- and (S,S)-2,7-diaminosuberic acid and (S,S)-o-phenylenebis(alanine))

RN 330160-19-5 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-3,11-bis[(1S)-1-phenylethyl]-, (2S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b uspatall
FILE 'USPATFULL' ENTERED AT 10:59:46 ON 12 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:59:46 ON 12 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l15

L15 ANSWER 1 OF 1 USPATFULL on STN
AN 2005:261958 USPATFULL
TI Tyrosine kinase inhibitors
IN Trotter, B. Wesley, Glenside, PA, UNITED STATES
PI US-20050227988 A1 20051013
AI 2003US-000510610 A1 20030408 (10)
2003WO-US00012457 20030408
20041008 PCT 371 date
PRAI 2002US-000372232P 20020412 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2093
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **615557-39-6P 615557-40-9P 615557-41-0P**
615557-42-1P 615557-43-2P 615557-44-3P
615557-45-4P 615557-46-5P
(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615557-39-6 USPATFULL

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-

hexahydro-11-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-40-9 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-41-0 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-42-1 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-43-2 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 615557-42-1
CMF C21 H23 Br N2 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 615557-44-3 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl- (9CI) (CA INDEX NAME)



RN 615557-45-4 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-46-5 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



IT 615557-51-2P 615557-52-3P 615557-53-4P
615557-54-5P 615557-55-6P 615557-56-7P
(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase

inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615557-51-2 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)



RN 615557-52-3 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)



RN 615557-53-4 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-11-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 615557-54-5 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 615557-55-6 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine-3,11(2H)-dicarboxylic acid, 1,4,5,6-tetrahydro-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 615557-56-7 USPATFULL
CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 10:13:44 ON 12 JUL 2007)

     FILE 'HCAPLUS' ENTERED AT 10:15:32 ON 12 JUL 2007
L1             1 US20050227988/PN OR (US2004-510610 OR WO2003-US12457 OR US2002-

     FILE 'REGISTRY' ENTERED AT 10:17:03 ON 12 JUL 2007

     FILE 'HCAPLUS' ENTERED AT 10:17:03 ON 12 JUL 2007
L2               TRA L1 1- RN :       36 TERMS

     FILE 'REGISTRY' ENTERED AT 10:17:03 ON 12 JUL 2007
L3            36 SEA L2
L4            14 NC2NC2-C6-NC7/ES AND L3
L5             8 (C20H23BRN2 OR C19H21BRN2 OR C26H26BR2N2 OR C21H23BRN2O) AND NC

     FILE 'HCAPLUS' ENTERED AT 10:23:45 ON 12 JUL 2007
L6             1 L5

     FILE 'REGISTRY' ENTERED AT 10:28:02 ON 12 JUL 2007
L7               STRUCTURE UPLOADED
L8             0 L7
L9            20 L7 FULL
                 SAV TEM L9 J610C21/A

     FILE 'HCAPLUS' ENTERED AT 10:49:52 ON 12 JUL 2007
L10            3 L9
L11            1 L10 AND L1
L12            2 L10 NOT L11
                 SEL HIT RN L12

     FILE 'REGISTRY' ENTERED AT 10:56:17 ON 12 JUL 2007
L13            5 E1-5

     FILE 'HCAOLD' ENTERED AT 10:56:58 ON 12 JUL 2007
L14            0 L9

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:57:06 ON 12 JUL 2007
L15            1 L9

=>
```